The purpose of this study is to determine whether the dipeptidyl peptidase IV (DPPIV)
inhibitor sitagliptin is effective in the treatment of cystic fibrosis-related diabetes
(CFRD). We hypothesize that sitagliptin will improve meal-stimulated insulin secretion.
Phase:
Phase 2
Details
Lead Sponsor:
University of British Columbia
Treatments:
Dipeptidyl-Peptidase IV Inhibitors Sitagliptin Phosphate